Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050
Aim: We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with EGFR-positive non-small-cell lung cancer (NSCLC). Methods: Post hoc analyses from ARCHER 1050 evaluated efficacy in patients who did and did not experience grade >= 2 skin AEs with dacomitinib. Landmark analyses were performed at 3 and 6 months. Results: In patients who had skin AEs (72.2%) vs. those who did not (27.7%), median progression-free survival was 16.0 vs. 9.2 months, median overall survival (OS) was 37.7 vs. 21.6 months, and objective response rate was 80.2 vs. 61.5%; OS was improved at 3 and 6 months landmark analyses. Conclusion: Presence of grade >= 2 skin AEs was associated with numerically improved efficacy and represents a valuable biomarker of treatment outcome with dacomitinib in patients with advanced NSCLC. Clinical Trial Registration: NCT01774721 (ClinicalTrials.gov)
第一作者机构：[1]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Oncol 2,Xiangya Sch Med, Changsha 410013, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Pu Xingxiang,Li Juan,Zhang Bo,et al.Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050[J].FUTURE ONCOLOGY.2024,20(37):2971-2982.doi:10.1080/14796694.2024.2404762.
APA：
Pu, Xingxiang,Li, Juan,Zhang, Bo,Zhang, Jinyao,Mok, Tony S....&Wu, Lin.(2024).Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.FUTURE ONCOLOGY,20,(37)
MLA：
Pu, Xingxiang,et al."Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050".FUTURE ONCOLOGY 20..37(2024):2971-2982
